Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I)‘s stock had its “buy” rating reissued by equities research analysts at Aegis in a report released on Thursday.

Other equities research analysts have also issued research reports about the company. Maxim Group set a $6.00 target price on Intellipharmaceutics International and gave the company a “buy” rating in a research report on Saturday, October 15th. Zacks Investment Research upgraded Intellipharmaceutics International from a “sell” rating to a “buy” rating and set a $3.00 price target on the stock in a report on Tuesday, October 18th. Finally, Brean Capital set a $8.00 price target on Intellipharmaceutics International and gave the stock a “buy” rating in a report on Monday, October 17th.

Shares of Intellipharmaceutics International (NASDAQ:IPCI) traded down 3.00% on Thursday, hitting $2.91. The stock had a trading volume of 186,522 shares. The company has a 50-day moving average of $2.87 and a 200 day moving average of $2.04. The company’s market capitalization is $84.29 million. Intellipharmaceutics International has a 52 week low of $1.41 and a 52 week high of $3.35.

COPYRIGHT VIOLATION NOTICE: “Intellipharmaceutics International Inc. (IPCI) Receives “Buy” Rating from Aegis” was first reported by Daily Political and is the propert of of Daily Political. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this news story can be read at http://www.dailypolitical.com/2016/11/29/intellipharmaceutics-international-inc-ipci-receives-buy-rating-from-aegis.html.

A hedge fund recently bought a new stake in Intellipharmaceutics International stock. Atria Investments LLC purchased a new stake in Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSE:I) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 67,727 shares of the company’s stock, valued at approximately $106,000. Atria Investments LLC owned approximately 0.27% of Intellipharmaceutics International at the end of the most recent quarter. 1.68% of the stock is currently owned by hedge funds and other institutional investors.

About Intellipharmaceutics International

IntelliPharmaCeutics International Inc is a Canada-based pharmaceutical company specializing in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

5 Day Chart for NASDAQ:IPCI

Receive News & Ratings for Intellipharmaceutics International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intellipharmaceutics International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.